|
|
||||||||
Division of Physiology, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
CORRESPONDENCE: F. Gaber, Unit for Experimental Asthma and Allergy Research, Division of Physiology, P.O. Box 287, The National Institute of Environmental Medicine, Karolinska Institutet, SE-17177 Stockholm, Sweden. Fax: 46 8300619. E-mail: Flora.Gaber{at}ki.se
Keywords:
-amylase, exhaled breath condensate, induced sputum, leukotriene B4, neutrophilic inflammation, pig house
Received: December 26, 2005
Accepted August 17, 2006
Leukotriene (LT)B4 in exhaled breath condensate (EBC) has been reported to be elevated in airway inflammation. The origin of leukotrienes in EBC is, however, not established.
The aims of this study are to measure LTB4 levels in EBC collected in two challenges characterised by a strong neutrophilic airway inflammation and to compare LTB4 levels in EBC with levels in sputum and saliva.
LTB4 and
Only four out of 102 EBC samples had detectable LTB4 (28100 pg·mL-1).
High levels of leukotriene B4 in saliva and the presence of leukotriene B4 in exhaled breath condensate only when
-amylase were measured in EBC from 34 healthy subjects exposed in a pig confinement building or to a lipopolysaccharide provocation. These markers were also measured in induced sputum in 11 of the subjects. For comparison, LTB4 and
-amylase were measured in saliva from healthy subjects.
-amylase activity was detected in the LTB4-positive samples. In contrast, LTB4 was detected in all examined sputum supernatants in the same study (median 1,190 pg·mL-1). The median LTB4 level in saliva was 469 pg·mL-1.
-amylase was detected, indicate that leukotriene B4 found in exhaled breath condensate is the result of saliva contamination. As leukotriene B4 was consistently present in sputum supernatants, exhaled breath condensate may be inappropriate for monitoring airway leukotriene B4.
This article has been cited by other articles:
![]() |
Z. L. Borrill, K. Roy, and D. Singh Exhaled breath condensate biomarkers in COPD Eur. Respir. J., August 1, 2008; 32(2): 472 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kullmann, I. Barta, B. Antus, M. Valyon, and I. Horvath Environmental temperature and relative humidity influence exhaled breath condensate pH Eur. Respir. J., February 1, 2008; 31(2): 474 - 475. [Full Text] [PDF] |
||||
![]() |
P. Montuschi Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 5 - 23. [Abstract] [PDF] |
||||
![]() |
W. J. Piotrowski, A. Antczak, J. Marczak, A. Nawrocka, Z. Kurmanowska, and P. Gorski Eicosanoids in Exhaled Breath Condensate and BAL Fluid of Patients With Sarcoidosis Chest, August 1, 2007; 132(2): 589 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kodric, A. N. Shah, L. M. Fabbri, and M. Confalonieri An Investigation of Airway Acidification in Asthma Using Induced Sputum: A Study of Feasibility and Correlation Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 905 - 910. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |